Trial Profile

The Effect of NovoMix 30, Levemir or NovoRapid (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-Diabetic Medication. A 24-Week, International, Prospective, Multi-Centre, Open-Labelled, Non-Interventional Study.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin aspart/insulin protamine aspart
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Acronyms A1chieve
Sponsors Novo Nordisk

20 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
20 Apr 2011 Actual end date reported as Dec 2010 by ClinicalTrials.gov.
19 Jul 2010 The results of this study will be available in 2011, according to a Novo Nordisk media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com